
Atea Pharmaceuticals, Inc.
AVIR·NASDAQ
Last updated as of 2026-04-06 02:39 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
AVIR stock price change
On the last trading day, AVIR stock closed at 5.76 USD, with a price change of 1.95% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreAVIR key data
Previous close5.76 USD
Market cap458.91M USD
Volume442.90K
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-1.95 USD
Net income (FY)−158.35M USD
Revenue (FY)0.00 USD
Next report dateMay 13, 2026
EPS estimate-
Revenue estimate-
Shares float62.77M
Beta (1Y)0.26

Atea Pharmaceuticals, Inc. overview
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Jean-Pierre Sommadossi
Headquarters
Boston
Website
ateapharma.com
Founded
2012
Employees (FY)
55
Change (1Y)
−1 −1.79%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
−2.88M USD
AVIR stock price forecast
According to technical indicators for AVIR stock, the price is likely to fluctuate within the range of 5.41–7.55 USD over the next week. Market analysts predict that the price of AVIR stock will likely fluctuate within the range of 5.25–8.82 USD over the next months.
Based on 1-year price forecasts from 18 analysts, the highest estimate is 10.83 USD, while the lowest estimate is 3.91 USD.
For more information, please see the
AVIR stock price forecast
page.
Latest AVIR stock news
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Finviz2026-02-24 12:03:57
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-05 21:12:19
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Finviz2026-02-24 12:03:57
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-05 21:12:19

